Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SporeVax-Anthrax
- Development stage
- Preclinical
- Lead developer
- Altimmune
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Mucosal
01
Overview
SporeVax-Anthrax is a preclinical-stage mucosal vaccine candidate developed by SporeGen for the prevention of anthrax. The platform utilizes *Bacillus subtilis* spores as a delivery vehicle to present *Bacillus anthracis* antigens to the mucosal immune system. By targeting mucosal surfaces, the vaccine aims to elicit both local and systemic immune responses, providing a non-invasive alternative to traditional injectable vaccines for biodefense and public health.
- Other names
- SporeVax - Anthrax
02
Targets
BclA (Bacillus collagen-like protein A)PA (Influenza polymerase acidic protein)γDPGA (Poly-γ-D-glutamic acid capsule)
Beyond the preview
Go deeper on SporeVax-Anthrax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SporeVax-Anthrax.